An overview of cannabis based treatment in Crohn's disease. (2nd April 2020)

• Record Type: Journal Article
• Authors: Naftali, Timna
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 14:Number 4(2020)
• Page Start: 253
• Page End: 257
• Publication Date: 2020-04-02
• Subjects: Cannabis -- marihuana -- Crohn's disease -- ulcerative colitis -- inflammatory bowel disease; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1080/17474124.2020.1740590
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Introduction : Cannabis use among inflammatory bowel disease (IBD) patients is common. There are many studies of various laboratory models demonstrating the anti–inflammatory effect of cannabis, but their translation to human disease is still lacking. Areas covered : The cannabis plant contains many cannabinoids, that activate the endocannabinoid system. The two most abundant phytocannabinoids are the psychoactive Tetrahydrocannabinol (THC), and the (mostly) anti–inflammatory cannabidiol (CBD). Approximately 15% of IBD patients use cannabis to ameliorate disease symptoms. Unfortunately, so far there are only three small placebo controlled study regarding the use of cannabis in active Crohns disease, combining altogether 93 subjects. Two of the studies showed significant clinical improvement but no improvement in markers of inflammation. Expert opinion : Cannabis seems to have a therapeutic potential in IBD. This potential must not be neglected; however, cannabis research is still at a very early stage. The complexity of the plant and the diversity of different cannabis chemovars create an inherent difficulty in cannabis research. We need more studies investigating the effect of the various cannabis compounds. These effects can then be investigated in randomized placebo controlled clinical trials to fully explore the potential of cannabis treatment in IBD.